Ocrelizumab, CAS 637334-45-3

Product Description: Ocrelizumab is an anti-CD20 antibody that depletes circulating immature and mature B cells but spares CD20-negative plasma cells. The effector mechanisms of Ocrelizumab are complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. Ocrelizumab is the first monoclonal antibody for secondary primary progressive multiple sclerosis (PPMS)[1].

Applications: COVID-19-immunoregulation

Formula: N/A

References: [1]Mulero P, et al. Ocrelizumab: a new milestone in multiple sclerosis therapy. Ther Adv Neurol Disord. 2018 May 10;11:1756286418773025.

CAS Number: 637334-45-3

Molecular Weight: N/A

Compound Purity: 95.00

Research Area: Inflammation/Immunology

Solubility: H2O

Target: CD20

• SKU: MEXHY-P9960-1
• Manufacturer: MedChemExpress
• Manufacturer SKU: HY-P9960-1
• Package Unit: 1 mg
• Quantity Unit: STK
• Conjugate: Unconjugated